Clade Therapeutics
Clade Therapeutics is a biopharmaceutical company established in 2020 and based in Cambridge, Massachusetts. The company specializes in the discovery and development of scalable, off-the-shelf stem cell-based medicines aimed at treating a variety of diseases, including cancer and autoimmune disorders. Clade Therapeutics integrates advancements in stem cell biology, immunology, regenerative medicine, and gene editing to create next-generation cell therapies. Its initial focus centers on developing therapies utilizing T cells and other immune cells, thereby enhancing the accessibility and effectiveness of stem cell-derived treatments for patients.
1 past transactions
Gadeta
Acquisition in 2023
Gadeta is a research and development company focused on creating innovative immunotherapies for cancer treatment. It has developed a technology platform that utilizes combinatorial T cell receptor exchange to produce optimized gamma delta T-cell receptors with enhanced anti-cancer properties. Gadeta’s primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), shows significant therapeutic potential for targeting and eliminating both hematological and solid tumors. The company's approach leverages high-affinity gamma delta TCRs expressed on alpha beta T cells, which possess superior proliferation capacity, aiming to improve outcomes for patients with advanced malignancies. Through its research, Gadeta seeks to contribute to the eradication of cancer and enhance treatment efficacy across various types of tumors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.